Senseonics Holdings, Inc. (SENS) Stock Price & How to Invest

Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin of the upper arm. Unlike the disposable adhesive sensors from Dexcom and Abbott that last roughly 10 to 15 days, Eversense is designed for long-term wear, and the current Eversense 365 version is approved for up to one year on a single sensor, paired with a removable transmitter and a phone app. The long-wear, low-maintenance profile is the company's core differentiator in an otherwise patch-dominated category.

Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Senseonics Holdings, Inc.'s investor relations page or your broker.

• Full-year 2025 revenue: ~$35.3M (up from ~$22.5M in 2024)
• Q1 2026 revenue: ~$11.7M (up ~87% year over year)
• Full-year 2026 revenue guidance: ~$60M to $64M (raised; ~70-82% growth)
• Q1 2026 net loss: ~$32.3M (vs ~$14.3M a year earlier)
• Cash, equivalents and investments: ~$64.6M as of March 31, 2026 (debt ~$35.2M)
• Market capitalization: ~$280M (early June 2026)

These figures describe a speculative growth company, not a mature one: revenue is rising quickly off a small base while net losses remain large relative to sales. Cash on hand and recent financing support the Eversense 365 launch and pipeline, but continued losses mean future capital raises are possible. All figures are approximate and tied to the asOf date; verify against the latest filings before acting.

There are three common ways to get SENS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SENS sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where SENS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

If you believe a once-a-year implantable sensor is a durable point of differentiation in the crowded CGM market and that Senseonics can keep growing patient starts while improving margins after taking commercialization in-house, then SENS is a way to express that view. It remains a speculative small-cap: revenue is still modest, net losses are large, and the company faces two far bigger and better-funded competitors. Position sizing and risk tolerance matter more here than with an established profitable company, and the descriptive purpose of this page is to explain how to invest, not whether you should.

Whether SENS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SENS a buy?, and where the stock could go from here in the SENS stock forecast.

For income investors, whether SENS pays a dividend and how the payout looks is covered in does SENS pay a dividend?